Paul McKenzie is convinced his $US3 billion ($4.8 billion) insurance policy is about to pay off.
Before McKenzie became chief executive of the $115 billion biotechnology giant CSL in March 2023, he spent almost four years as chief operating officer, a good chunk of which was spent helping the company navigate the supply chain problems created by the pandemic.
Loading...
James Thomson is senior Chanticleer columnist based in Melbourne. He was the Companies editor and editor of BRW Magazine. Connect with James on Twitter. Email James at j.thomson@afr.com
